Rifampicin-resistant Mycobacterium tuberculosis complex in Niger: A 5-year retrospective analysis (2017–2022)

Résumé fourni par la source

Background: Rifampicin-resistant Mycobacterium tuberculosis complex is a growing burden globally and is classified as a critical organism. This study aimed to determine the prevalence of Rifampicin-resistant tuberculosis (RR-TB) and associated risk factors in Niger Republic. Methods: This was a retrospective study, conducted from January 1, 2017, to December 2022 at GeneXpert sites in Niger. GeneXpert MTB/RIF was used to detect Mycobacterium tuberculosis complex (MTC) and the resistance to rifampicin. Multivariate logistic analysis was performed to identify risk factors for rifampicin resistance in Niger. Results: A total of 12970 patients were enrolled. The median age of patients was 39 years, with male predominant, sex ratio of 2.70. The overall, prevalence of MTC was 37.69% (4889/12970), among this 4.45% (210/4889) were children. Out of 4889 MTC positive cases, 479 (9.79%) were rifampicin-resistant, all from pulmonary tuberculosis: 111 (23,57%) new cases, 195 (41,40%) therapeutic failure, 153 (32,48%) relapsed cases, 12 (2,55%) treatment abandonment. Based on the univariate analysis, therapeutic failure (p=0.001), relapsed cases (p=0.001), and treatment abandonment (p=0.005), were significantly related to rifampicin resistance in Niger. Based on the multivariate analysis, only therapeutic failure (AOD: 6.62, 95%CI: 5.17-8.51, p<0.001) and relapsed cases (AOD: 3.08, 95%CI: 2.39-3.98, p<0.001) were the independents factors associated with rifampicin resistance. Conclusion: The prevalence of MTC resistance to rifampicin was relatively high in Niger. Therapeutic failure and relapsed cases represented the major factors favoring rifampicin resistance.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.